TITLE

Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)

AUTHOR(S)
Formica, Vincenzo; Cereda, Vittore; di Bari, Maria-Giovana; Grenga, Italia; Tesauro, Manfredi; Raffaele, Palmirotta; Ferroni, Patrizia; Guadagni, Fiorella; Roselli, Mario
PUB. DATE
December 2013
SOURCE
Medical Oncology;Dec2013, Vol. 30 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
92576931

 

Related Articles

  • Antineoplastics.  // Reactions Weekly;5/14/2011, Issue 1351, p9 

    The article presents four cases of patients who developed interstitial lung disease while receiving standard chemotherapy with fluorouracil + calcium levofolinate + oxaliplatin, fluorouracil + calcium levofolinate + irinotecan, or capecitabine + oxaliplatin, and bevacizumab for metastatic...

  • Bevacizumab/fluorouracil/folinic acid/irinotecan.  // Reactions Weekly;May2015, Vol. 1552 Issue 1, p39 

    The article describes the case of patients who developed neutropenic sepsis, epistaxis and hypertension while receiving bevacizumab, fluorouracil, folinic acid and irinotecan treatment for metastatic cancer, referencing a research published in the journal "Clinical Colorectal Cancer."

  • Cancer Chemotherapy Update - Leucovorin, Fluorouracil, and Irinotecan (FOLFIRI) Plus Bevacizumab for Metastatic Colorectal Cancer. Massoud, R. Vivian; Solimando, Jr, Dominic A.; Waddell, J. Aubrey // Hospital Pharmacy;Oct2011, Vol. 46 Issue 10, p748 

    The article reports on the dispensing, preparation, and administration of Leucovorin, Fluorouracil, and Irinotecan (FOLFIRI) with Bevacizumab for metastatic colorectal cancer treatment (mCRC). It says that FOLFIRI plus bevacizumab had shown more tolerable and effective in patients with mCRC and...

  • FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping. Yeh, Yung-Sung; Huang, Meng-Lin; Chang, Se-Fen; Chen, Chin-Fan; Hu, Huang-Ming; Wang, Jaw-Yuan // Medical Principles & Practice;Sep2014, Vol. 23 Issue 5, p478 

    Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A...

  • Bevacizumab in Colorectal Cancer. Sonpavde, Guru // New England Journal of Medicine;10/14/2004, Vol. 351 Issue 16, p1690 

    The article presents a letter to the editor in response to the article "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," by H. Hurwitz, L. Fehrenbacher, W. Novotny, et al.

  • Bevacizumab in Colorectal Cancer. Sharieff, Waseem // New England Journal of Medicine;10/14/2004, Vol. 351 Issue 16, p1690 

    The article presents a letter to the editor in response to the article "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," by H. Hurwitz, L. Fehrenbacher, W. Novotny, et al.

  • Bevacizumab in Colorectal Cancer. Hurwitz, Herbert I.; Novotny, William; Kabbinavar, Fairooz // New England Journal of Medicine;10/14/2004, Vol. 351 Issue 16, p1690 

    The article presents a response to letters to the editor written about the article "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," by H. Hurwitz, L. Fehrenbacher, W. Novotny, et al.

  • Erratum.  // Oncology;2009, Vol. 77 Issue 3/4, p256 

    A correction to the article "Phase IV Study of Bevacizumab in Combination With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer," which appeared in a 2009 issue of "Oncology" is presented.

  • Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Chong, G.; Cunningham, D. // British Journal of Cancer;3/27/2006, Vol. 94 Issue 6, p937 

    A letter to the editor is presented in response to comments made on the authors' article "Capecitabine and Mitomycin C in Patients With Metastatic Colorectal Cancer Resistant to Fluorouracil and Irinotecan."

  • Improving overall survival in colorectal cancer. Fricker, Janet // British Journal of Hospital Medicine (17508460);Apr2008, Vol. 69 Issue 4, p190 

    The article reports on the effectiveness of Irinotecan plus bevacizumab combined with an infusional schedule of fluorouracil (5FU) in improving the overall survival in patients with metastatic colorectal cancer, according to a study. The researchers state that an infusional schedule of FU should...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics